This letter to the editor highlights additional analyses to add to the recently reported study by Rugo et al., regarding abemaciclib treatment for HR+/HER2− breast cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265371 | PMC |
| http://dx.doi.org/10.1002/onco.13781 | DOI Listing |
Publication Analysis
Top Keywords
article rugo
4
rugo letter
4
letter editor
4
editor highlights
4
highlights additional
4
additional analyses
4
analyses add
4
add reported
4
reported study
4
study rugo
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!